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Long-lived plasma cells (LLPCs) constitutively 
secrete antibody to neutralize antigen immedi-
ately upon reinfection, whereas memory B cells 
(MBCs) produce antibody only upon restimu-
lation by specific antigen (Manz et al., 1997; 
Slifka et al., 1998). Although preexisting serum 
antibody titers correlate with vaccine efficacy, 
the importance of the MBC response in con-
ferring protection to reinfection has remained 
controversial  (Zinkernagel  and  Hengartner, 
2006). As both LLPC and MBC have been re-
tained through mammalian evolution, these cell 
types must have distinct functions that remain to 
be fully delineated.
Hapten-based studies have reported that the 
affinities of LLPC B cell receptors (BCRs) are 
higher than those of MBC (Smith et al., 1997). 
Studies  using  fixed  BCR  demonstrated  that 
cells with high-affinity antigen receptors were 
recruited preferentially to the LLPC pool (Phan 
et al., 2006). In contrast, MBC can be formed 
even when BCR affinities are low (Dal Porto 
et al., 2002). Because of the reduced stringency 
of selection, the repertoire of the MBC pool 
may be more diverse and reactive to pathogen 
variants than a more oligoclonal LLPC popula-
tion. Experiments with influenza and HIV have 
supported these predictions, although several of 
these studies suggest that MBCs achieve broader 
reactivity primarily through somatic hypermu-
tation and affinity maturation that occurs after 
secondary encounter with heterologous viruses 
(Wrammert et al., 2008, 2011; Galli et al., 2009; 
Scheid et al., 2009).
One caveat to these conclusions is the recent 
finding  that  isotype-switched  MBCs,  which 
dominate  the  initial  antibody  recall  response, 
have a limited ability to form new germinal 
centers and thus may be incapable of undergoing 
further affinity maturation (Dogan et al., 2009; 
Pape et al., 2011). Based on these studies, we 
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Memory B cells (MBCs) and long-lived plasma cells (LLPCs) persist after clearance of infec-
tion, yet the specific and nonredundant role MBCs play in subsequent protection is unclear. 
After resolution of West Nile virus infection in mice, we demonstrate that LLPCs were 
specific for a single dominant neutralizing epitope, such that immune serum poorly inhib-
ited a variant virus that encoded a mutation at this critical epitope. In contrast, a large 
fraction of MBC produced antibody that recognized both wild-type (WT) and mutant viral 
epitopes. Accordingly, antibody produced by the polyclonal pool of MBC neutralized WT 
and variant viruses equivalently. Remarkably, we also identified MBC clones that recognized 
the mutant epitope better than the WT protein, despite never having been exposed to the 
variant virus. The ability of MBCs to respond to variant viruses in vivo was confirmed by 
experiments in which MBCs were adoptively transferred or depleted before secondary 
challenge. Our data demonstrate that class-switched MBC can respond to variants of the 
original pathogen that escape neutralization of antibody produced by LLPC without a 
requirement for accumulating additional somatic mutations.
© 2011 Purtha et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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We detected DIII-specific LLPCs at 100 d after infection by 
ELISPOT (Fig. 1 B) and, similar to the ELISA data with 
serum, a substantial (9.3-fold, P < 0.01) reduction in binding 
to the DIII-LR epitope was observed. As an independent 
measure of LLPC specificity, we analyzed bone marrow cells 
for intracellular binding to a bivalent fusion protein com-
posed of WNV DIII or DIII-K307E/T330I and human   
1 Fc (DIII-FcHu, DIII-K307E/T330I FcHu). We identified a 
small population of plasma cells that recognized DIII that was 
not present in mice infected with an unrelated virus (Fig. 1,   
C and D). Importantly, there were notably fewer LLPCs   
that  recognized  DIII-K307E/T330I  compared  with  DIII   
(P < 0.005). Thus, after WNV infection in C57BL/6 mice, a 
significant fraction of LLPC expressed BCRs that are re-
stricted to a single immunodominant epitope.
Given the epitope specificity of the LLPC response, we 
hypothesized that the antibody derived from these cells would 
strongly neutralize homologous WNV but might be impaired 
at neutralizing a variant (WNV-K307E) with a single muta-
tion  introduced  at  the  dominant  epitope.  Convalescent 
serum from either WNV-infected or vaccinated mice was 
tested in neutralization assays with the homologous WNV-WT 
or variant WNV-K307E. With serum collected 60 d after 
WNV-WT infection, we observed a reduction (8.5-fold, 
P < 0.05) in the EC50 value for WNV-K307E compared 
with WNV-WT (Fig. 2, A and B). Similar results were 
observed with serum from mice 60 d after immunization 
with a formalin-inactivated vaccine, with less efficient neu-
tralization of the variant WNV-K307E virus (Fig. 2, A and B).
To confirm these results, we performed protection exper-
iments  by  transferring  immune  serum  from  vaccinated 
mice  immediately  before  challenge  with  WNV-WT  or 
WNV-K307E. Transfer of 1 µl of immune serum, but not 
hypothesized that MBC, but not LLPC, would recognize effi-
ciently variant antigens before secondary encounter with het-
erologous viruses. To test this, we used a mouse model of  West   
Nile virus (WNV) infection with a WT and variant virus that   
differ only by a single amino acid in a dominantly neutralizing 
epitope. Our results suggest that LLPCs function to prevent 
secondary infection with homologous viruses, whereas MBCs 
generated during the primary response can recognize pathogen 
variants that escape neutralization of preexisting serum anti-
body produced by LLPCs.
RESULTS AND DISCUSSION
In mice, both B cells and antibody are required for survival 
after WNV infection (Diamond et al., 2003). Strongly neu-
tralizing mouse monoclonal and polyclonal antibodies bind 
to the lateral ridge (LR) epitope on domain III (DIII; DIII-LR, 
residues K307, T330, and T332) of the viral E glycoprotein 
(Beasley and Barrett, 2002; Oliphant et al., 2005, 2007). 
Virtually all antibodies specific for this epitope can be identi-
fied by comparing binding to WT and loss-of-function pro-
teins with mutations at two of the critical contact residues 
(K307E and T330I). We measured a significant reduction 
(7.4-fold,  P  <  0.01)  in  serum  antibody  recognition  of 
DIII-K307E/T330I in comparison with WT DIII at days 
30–100 after infection in WT C57BL/6 mice (Fig. 1 A). 
Serum  antibody  titers  against  this  epitope  were  sustained   
as late as 500 d after infection, a time at which short-lived 
plasma cell–derived antibody titers wane, suggesting that 
the LLPC population was skewed toward recognizing the 
DIII-LR epitope.
To measure the frequency of WNV-specific LLPCs, we 
interrogated bone marrow cells from infected mice for their 
ability to secrete IgG that recognized WT and variant DIII. 
Figure 1.  LLPCs recognize the K307/T330,  
but not a mutant K307E/T330I epitope. 
(A) Mice were infected with WNV, and serum 
was collected at the indicated time points 
after infection. Levels of DIII or DIII-K307E/
T330I–specific IgG were measured by ELISA. 
Endpoint titers are expressed as the reciprocal 
serum dilution that was 3 SD above back-
ground. The data reflect 6–10 mice per time 
point from four experiments. (B) Bone marrow 
cells were collected at the indicated time 
points after WNV infection and DIII or DIII-
K307E/T330I–specific plasma cells were enu-
merated by ELISPOT assay. The data reflect six 
to nine mice per time point from four experi-
ments. (C) Bone marrow cells were collected 
from mice infected with WNV or Chikungunya 
virus (CHIKV) and antigen-specific plasma 
cells were enumerated by intracellular stain-
ing. Data are shown as percentage of total 
B220CD138+ cells. The percentage of cells staining as DIII or DIII-K307E/T330I–specific LLPC in CHIKV-infected mice was considered background and 
subtracted (0.1%). The data reflect five mice from three experiments. Horizontal bars in A–C indicate the mean. (D) Representative flow cytometry 
plots showing DIII or DIII-K307E/T330I–specific plasma cells from mice at 60 d after infection with WNV or CHIKV. Statistical significance (***, P < 0.001; 
**, P < 0.01; *, P < 0.05) was determined by an unpaired, two-tailed Student’s t test.JEM Vol. 208, No. 13  2601
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a significant decrease in binding to the K307E/
T330I DIII mutant relative to the WT DIII pro-
tein (P > 0.1).
As an independent measure of MBC frequency 
and specificity, we determined the relative number 
of virus-specific MBC by flow cytometry. Immune 
splenocytes were stained for MBC markers (CD19, 
CCR6, and CD80; Bhattacharya et al., 2007) and 
DIII-FcHu or DIII-K307E/T330I-FcHu. We defined 
a  population  of  isotype-switched  CCR6+CD80+  MBCs 
specific to DIII in WNV immune mice, but not in mice in-
fected with an irrelevant virus (Fig. 3, B and C; and Fig. S1 A). 
The antigen specificity was confirmed by sorting DIII+ MBCs, 
activating them in vitro, and testing the supernatant by ELISA 
(Fig. S1 B). DIII+-sorted MBCs recognized both DIII and 
DIII-K307E/T330I,  whereas  DIII  MBC  from  WNV-
immune  mice  failed  to  produce  antibody  that  recognized 
DIII. All DIII-specific MBCs were within the CCR6+CD80+ 
gate, as adoptive transfer of isotype-switched CD80CCR6 
cells from WNV-immune mice or CD80+CCR6+ cells from 
naive mice failed to produce anti-DIII antibody upon chal-
lenge with WNV-WT (Fig. S1 C). The kinetics of antigen-
specific MBC accumulation and maintenance was consistent 
in both the LDA and flow cytometric experiments (Fig. 3,   
A and B). In contrast to the LDA, we observed a small decrease 
by flow cytometry in the frequency of MBCs that recognized 
DIII-K307E/T330I at days 30 and 60 after infection. None-
theless, the LDA and flow cytometry experiments both suggest 
that compared with the LLPC pool, MBCs contain a much 
larger frequency of B cell clones that recognize the mutant 
DIII-K307E/T330I. We calculated the frequency of cells that 
recognize DIII-K307E/T330I relative to DIII between MBCs 
and LLPCs. At each time point, MBCs, whether enumer-
ated by LDA or flow cytometry, were enriched in anti-
bodies that recognized DIII-K307E/T330I compared with 
LLPCs (Fig. 3 D). Therefore, cells in the MBC compartment 
saline, into naive 5-wk-old mice protected from WNV-WT 
challenge (100 vs. 5% survival, P < 0.001; Fig. 2 C). In com-
parison, the same immune serum did not improve survival 
significantly after challenge with the variant virus WNV-K307E 
(56 vs. 35% survival, P > 0.05). WNV-K307E was mildly 
attenuated in mice, as reported previously (Zhang et al., 2009). 
In mice receiving immune serum, viremia was reduced at 36 h 
(10-fold, P < 0.001) and 72 h (11-fold, P < 0.05) after   
infection with WNV-WT (Fig. 2 D). However, the same 
serum failed to reduce viremia after WNV-K307E infection 
(P > 0.2). Thus, LLPC-derived antibody was inefficient at 
controlling infection with a variant WNV that was altered at a 
single amino acid within the dominant neutralizing epitope.
To evaluate the frequency of MBCs specific to the neutral-
izing epitope, we used two approaches: (1) limiting dilution 
analysis (LDA) of supernatant from cultures of stimulated MBCs 
and (2) direct enumeration of antigen-specific MBCs by flow 
cytometry. At different time points after WNV-WT infection, 
CD19+ B cells from the spleen were diluted serially, antibody 
secretion was induced (Amanna and Slifka, 2006), and superna-
tants were tested for reactivity to DIII or DIII-K307E/T330I. 
At day 30 after infection, there were, on average, 26 DIII-
specific MBCs per 106 B cells (Fig. 3 A). This frequency in-
creased to 57 at day 60 but waned to 7 DIII-specific MBCs per 
106 B cells by day 300. Next, we compared the relative fre-
quencies of DIII and DIII-K307E/T330I-specific MBCs. In 
contrast to antibody produced by LLPCs, we did not measure 
Figure 2.  LLPCs weakly neutralize a variant WNV.  
(A) Mice were infected with WNV or WNV-K307E (left) or  
immunized with an inactivated WNV vaccine (right), and sera 
were collected at day 60. Neutralizing antibody titers were 
measured by plaque reduction assay. Means and SD are shown 
of six experiments. (B) EC50 titers were calculated from neu-
tralization curves of WNV-WT or WNV-K307E incubated with 
serum from WNV-infected or vaccinated mice. Means and SD 
are shown from three or six experiments. The dashed line rep-
resents the limit of detection of assay. (C) Mice were injected 
with 1 µl WNV immune serum or PBS before infection with 
WNV or WNV-K307E or PBS. Data reflect 20–26 mice per 
group in three experiments. Survival differences were deter-
mined by the log-rank test. NS, not significant. (D) Mice were 
injected with 1 µl of immune or PBS immediately before infec-
tion with WNV (left) or WNV-K307E (right) mice. Viral RNA in 
serum was measured by qRT-PCR. Means and SD are shown of 
two experiments with five mice per group. Statistical signifi-
cance (***, P < 0.001; **, P < 0.01; *, P < 0.05) was determined 
by an unpaired, two-tailed Student’s t test.2602 Memory B cells are adept at recognizing virus variants | Purtha et al.
assay detection (Fig. 4 A). To corroborate these findings, we 
isolated  single  DIII-specific  or  DIII-K307E/T330I-specific 
MBCs by cell sorting and expanded them in culture on feeder 
cells expressing BAFF and CD40L. Although DIII-K307E/
T330I-specific MBC clones were isolated (Fig. 4 B), others 
produced  antibody  that  recognized  DIII  and  DIII-K307E/
T330I equivalently (Fig. 4 C). Moreover, one clone (2F2) 
bound the variant DIII-K307E/T330I protein better than the 
WT protein. To confirm this observation, the heavy and light 
chain genes of 2F2 were cloned and expressed ectopically. 
were more poised, compared with LLPCs, to recognize 
variant DIII carrying mutations that cause functional escape 
from neutralization.
Given the broader antigen specificity of the MBC popula-
tion, we asked whether a subset of MBCs encoded antibody 
that preferentially recognized the variant epitope that was not 
present during primary infection. Remarkably, wells that con-
tained single B cell clones as isolated by LDA revealed MBC 
specificities that recognized the mutant DIII-K307E/T330I 
but bound WT DIII so poorly that it was below the limit of 
Figure 3.  MBCs recognize mutant DIII-K307E/T330I 
epitopes. (A) Mice were infected with WNV, splenocytes were 
collected at the indicated time points, and CD19+ B cells were 
isolated by positive selection. The frequency of DIII- or DIII-
K307E/T330I-specific IgG+ MBC was assessed by LDA. Virus-
specific IgG in supernatants from LDA cultures were measured 
by ELISA and frequencies of virus-specific MBC determined by 
linear regression analysis. The limit of detection was 2 MBCs 
per 106 B cells (dashed line), and data reflect 5–14 mice per 
group from four experiments. P-values were determined using 
an unpaired, two-tailed Student’s t test. (B) The frequency of 
splenic DIII- or DIII-K307E/T330I-specific MBC was assessed by 
flow cytometry. The percentage of cells staining as DIII+ or 
DIII-K307E/T330I+ MBC in CHIKV-infected mice was considered 
background and subtracted (6.1 and 5.4 MBCs per 106 CD19+ 
cells). Data reflect 7–11 mice per group from five experiments 
and are displayed as frequency of antigen-specific MBCs per 
106 CD19+ cells. P-values were determined using an unpaired, 
two-tailed Student’s t test. (C) Flow cytometry plots were from 
B and show MBC recognizing DIII or DIII-K307E/T330I from 
WNV- or CHIKV-infected mice. (D) Ratio of frequency of DIII-
K307E/T330I- to DIII-specific MBC or LLPC in individual mice 
as measured by flow cytometry, LDA, and ELISPOT. MBC fre-
quencies were shown in A and B, and LLPC frequencies were 
from Fig 1 (B and C). P-values were determined by the Mann-
Whitney test (***, P < 0.001; **, P < 0.01; *, P < 0.05). Horizon-
tal bars indicate the mean.
Figure 4.  MBC clones can recognize variant epi-
tope better than WT DIII. (A) Percentage of MBC 
clones that bind DIII, both DIII and DIII-K307E/T330I, or 
DIII-K307E/T330I by ELISA. Positive-scoring wells of the 
lowest dilution from LDA in A were assigned specifici-
ties based on binding to DIII and DIII-K307E/T330I. 
Data represent 9.8 clones per mouse from 8–14 mice 
(low frequency of MBC at day 300 precluded analysis). 
(B and C) Individual WNV-specific MBCs were sorted 
and cultured. Supernatant was tested for binding to 
DIII or DIII-K307E/T330I by ELISA to identify DIII-LR–
specific (B) or DIII–cross-reactive (C) MBC. Data repre-
sent four independent experiments. (D) Clone 2F2 was 
expressed ectopically in 293T cells and supernatant 
was tested for binding to DIII or DIII-K307E/T330I. Rep-
resentative results are shown, and statistical signifi-
cance was determined using a paired, two-tailed 
Student’s t test using data from four independent  
experiments performed in duplicate (*, P < 0.01).JEM Vol. 208, No. 13  2603
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does not affect LLPCs (Uchida et al., 2004; Ahuja et al., 2008; 
DiLillo et al., 2008). In the absence of MBCs, mice would be 
predicted to respond more poorly to viral variants. To test this, 
mice were immunized with DIII of a related flavivirus, Japanese 
encephalitis virus (JEV). Although JEV and WNV share 75% 
amino  acid  sequence  identity  (Sumiyoshi  et  al.,  1987),  the 
cross-reactive DIII-specific antibody generated after immuniza-
tion with JEV DIII is not directed at the DIII-LR epitope and 
does not efficiently neutralize WNV (unpublished data). 60 d 
after immunization with JEV-DIII, mice were administered 
CD20 or isotype control mAb. After 2 wk, the depletion of 
CD19+ B cells was confirmed by analysis of peripheral blood. 
Notably, 293T cells transfected with 2F2 heavy and light chain 
genes produced antibody that recognized DIII-K307E/T330I 
better than WT DIII (Fig. 4 D). These results suggest that 
antigen specificities can be generated within the MBC com-
partment through mutation in the primary germinal center 
reaction, which preferentially recognizes variant epitopes.
To define the diversity within the MBC compartment, 
we analyzed the immunoglobulin gene sequences of individual 
WNV-specific MBCs. The analysis of nine cross-reactive clones 
revealed vast sequence variation within the complementarity-
determining regions (CDRs), with no apparent consensus for 
gene family or amino acid usage (Tables S1 and S2). Among 11 
DIII-LR–specific clones, we noted some conservation of the 
light chain V19-25 gene segment. For comparison, sequencing 
data from the previously generated DIII-LR–specific monoclo-
nal antibodies E16, E24, and E34 was included (Oliphant et al., 
2005). Still, heavy chain usage was variable, even at contact resi-
dues between E16 and K307/T330 previously identified by 
crystallographic analysis (Nybakken et al., 2005). Although a 
similar analysis on LLPCs was attempted, the low frequency 
(1%) of antigen-specific cells, low levels of cell surface BCR, 
and nonproliferative nature of these cells precluded isolation of 
individual WNV-DIII–specific LLPC clones. Still, the selection 
of MBCs with divergent immunoglobulin gene sequences is 
consistent with the broad reactivity of this population.
Because MBCs were better able to recognize DIII-K307E/
T330I than LLPCs were, we hypothesized that antibody de-
rived from these cells would more efficiently neutralize WNV-
K307E. To assess this, we tested the ability of antibody-containing 
supernatant from polyclonally stimulated MBCs to neutralize 
WT or variant WNV. Although the total antibody concentra-
tion in MBC culture supernatant was lower than in immune 
serum (500-fold less, not depicted), resulting in less inhibi-
tion,  antibody  produced  by  MBC  neutralized  WNV  and 
WNV-K307E equivalently (P > 0.9; Fig. 5 A). This contrasts 
with the relatively poor neutralizing activity of LLPC-derived 
antibody against WNV-K307E (Fig. 2 A).
We used two approaches to assess the ability of MBCs to 
respond to heterologous infection. We adoptively transferred 
CD19+CCR6+CD80+IgMIgDlin  MBCs  from  vacci-
nated C57BL/6J-Igha mice into antibody allotype-mismatched 
Ighb C57BL/6 mice and challenged recipients with either 
WNV-WT or WNV-K307E. Using IgG2aa-specific sec-
ondary antibodies, we detected MBC-derived antibody by 
ELISA. Transferred MBCs preferentially produced DIII-LR– 
specific antibodies when mice were challenged with WNV-
WT  (Fig.  5  B,  left),  suggesting  that  homotypic  MBCs 
recognizing the DIII-LR epitope outcompete the cross-reac-
tive MBCs in a secondary response, perhaps as a result of 
higher affinity for antigen. In contrast, MBCs produced anti-
bodies that recognized both DIII and DIII-K307E/T330I 
equivalently  when  recipient  mice  were  challenged  with 
WNV-K307E (Fig. 5 B, right).
To evaluate the ability of MBCs to recognize naturally oc-
curring viral variants without relying on adoptive transfer ex-
periments, we used a CD20 antibody that depletes MBCs but 
Figure 5.  MBCs can respond to and neutralize variant virus.  
(A) Neutralization curves of WNV-WT or WNV-K307E with supernatant 
from stimulated MBCs. Data reflects four independent experiments  
performed in duplicate. Error bars indicate SD. (B) IgHa MBCs (CD19+IgM
IgDlinCCR6+CD80+) from WNV-vaccinated mice were sorted and trans-
ferred into allotypic IgHb recipients and challenged with WNV-WT or 
WNV-K307E 1 d later. Specificity of the MBC-derived antibody at differ-
ent time points was determined by ELISA using an IgG2aa-specific detec-
tion antibody. Data reflects eight mice per group and is the average of 
five experiments (C) Mice were immunized with JEV-DIII and treated with 
B cell–depleting (CD20 mAb) or an isotype control antibody. Serum was 
tested before WNV infection (left) and at days 3 and 8 (right) after infec-
tion for IgG binding to WNV-DIII by ELISA. The data reflect a total of 
five to nine mice per group from three experiments. P-values were 
determined using an unpaired, two-tailed Student’s t test (*, P < 0.01).  
NS, indicates not significant.2604 Memory B cells are adept at recognizing virus variants | Purtha et al.
more strongly than the WT protein (Corti et al., 2010). This 
particular antibody is potently neutralizing across different clades, 
suggesting that antibodies with variant specificities may be func-
tionally relevant in the context of the breadth of the response.
MATERIALS AND METHODS
Viruses and quantification of viral burden. The WNV strain (3000.0259) 
was isolated in New York in 2000 and passaged once in C6/36 Aedes albopictus 
cells. Mice were inoculated subcutaneously in the footpad with 102 PFU of 
WNV diluted in Hanks balanced salt solution and 1% heat inactivated fetal 
bovine serum. The WNV-K307E strain was isolated as an in vivo escape 
mutant of the neutralizing humanized mAb E16 from brains of RAG1/ 
mice (Zhang et al., 2009) and was passaged once in C6/36 cells. CHIKV 
(La Reunion 2006-OPY1) was generated from an infectious clone (gift of   
S. Higgs, University of Texas Medical Branch, Galveston, TX) and passaged 
once in C6/36 cells. For viral RNA quantification, RNA was purified from 
serum samples using a Qia-Amp RNA recovery kit (QIAGEN) and copies 
were determined by TaqMan real-time reverse transcription PCR as previ-
ously described (Diamond et al., 2003).
Immunizations and immunodepletion. The West Nile Innovator vaccine 
was obtained commercially (Valley Vet Supply). Mice were administered two 
doses (100 µl each) of vaccine by intraperitoneal injection at days 0 and 1. DIII 
(residues 301–406) of JEV was expressed in E. coli using a pET21 vector and 
purified by oxidative refolding as previously described (Oliphant et al., 2005). 
Mice were immunized with 25 µg JEV-DIII and 20 µg CpG (Integrated DNA 
Technologies) in alum subcutaneously. For depletion of B cells, mice were 
administered 50 µg of an antibody against CD20 (MB20-11; Uchida et al., 
2004) by retroorbital injection. Depletion was confirmed by flow cytometric 
analysis of CD19+Ter119 cells from peripheral blood 2 wk after antibody 
treatment, and B cell reconstitution was confirmed at least 13 wk later.
Mice. C57BL/6 (WT and RAG1/) and C57BL/6J-Igh-1a Thy1a Gpi1a 
mice were purchased from The Jackson Laboratory. All mice were bred in the 
animal  facilities  of  the  Washington  University  School  of  Medicine  under 
pathogen-free conditions, and experiments were performed in compliance with 
Washington University Animal Studies guidelines. This study was performed in 
strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. The protocol 
was approved by the Institutional Animal Care and Use Committee at the 
Washington University School of Medicine (Assurance Number: A3381-01).
Flow cytometry and cell sorting. Single cell suspensions were generated 
from spleen or bone marrow. Lymphocytes were isolated by differential 
centrifugation (850 g, 10 min at room temperature) through a ficoll gradient 
composed of Histopaque-1119 and Histopaque-1077 (Sigma-Aldrich). Cells 
were resuspended in PBS containing 2% FBS (Hyclone) and incubated on 
ice with the directly conjugated antibodies. MAbs were purified from the 
following hybridomas (Bio-X-Cell): 2C11 (anti-CD3), GK1.5 (anti-CD4), 
53–6.7  (anti-CD8),  8C5  (anti–Gr-1),  TER119  (anti-Ter119),  and  1D3 
(anti-CD19). Antibodies were conjugated to Pacific Blue succinimidyl ester 
(Invitrogen) according to the manufacturer’s instructions. The following 
antibodies were purchased from eBioscience: anti–B220 (6B2) conjugated to 
PE-Cy7; anti-CD19 (ID3) conjugated to Alexa Fluor 700; anti-CD80 
(16-10A1) conjugated to PE; and anti-IgD (11–26) and anti-GL7 (GL-7) 
conjugated to biotin. The following antibodies were purchased from BD: 
anti-IgM (11/41) conjugated to PE-Cy5.5; anti-CCR6 (140706) conju-
gated to Alexa Fluor 647; anti-CD138 (281–2) conjugated to biotin; and 
anti-CD138 (281–2) conjugated to PE. Streptavidin conjugated to Qdot-605 
was purchased from Invitrogen. Cells were stained at 4°C for 30 min.
For staining of antigen-specific MBCs, cells were incubated with 0.8 µg of 
a  chimeric  fusion  protein  (DIII-FcHu)  of WNV-DIII  (or  a  mutant  DIII-
K307E/T330I) linked to a human Fc-1 heavy chain with a point mutation 
in the N-linked glycosylation site that abolishes Fc-R and C1q binding 
(Tao and Morrison, 1989). This protein was generated as follows: WNV DIII-Fc 
Mice were rested for 13 wk to allow restoration of naive CD19+ 
B cells before challenge with WNV. Antibody response to an 
irrelevant hapten was normal in these mice, demonstrating that 
the naive B cell pool had fully recovered, whereas in vitro MBC 
cultures revealed the continued absence of JEV-DIII–specific 
MBC at this time point (unpublished data).
To evaluate the contribution of MBCs to heterologous 
challenge, JEV-DIII–immunized control or CD20 mAb-
treated mice were infected with WNV. Serum was tested 
before WNV infection (Fig. 5 C, left), at day 3, and at day 8 
(Fig. 5 C, right) after infection for binding to WNV-DIII. 
Importantly, before and at day 3 after infection, both control 
and CD20 mAb-treated mice had equivalent levels of anti–
WNV-DIII IgG antibody that was derived exclusively from 
the initial JEV-DIII immunization (Fig. 5 C, P > 0.6). Thus, 
normal antibody titers derived from LLPCs were present in 
the CD20 mAb-treated mice. However, CD20 mAb-treated 
mice exhibited a reduced anti–WNV-DIII IgG response at 
day 8 in comparison with control mice (P < 0.001). Thus, 
MBC  generated  by  JEV-DIII  immunization  produced 
anti-WNV DIII antibody after heterologous challenge despite 
the presence of nonneutralizing antibody derived from LLPCs.
Our  data  support  a  model  in  which  broadly  reactive 
MBCs are generated upon primary pathogen exposure, ex-
panded without a requirement for further somatic hypermu-
tation after secondary challenge, and preferentially neutralize 
variant viruses better than LLPC-derived serum antibody. 
It also remains possible that IgM+ memory cells undergo ad-
ditional  somatic  hypermutation  as  they  differentiate  into 
IgG+ plasmablasts. Consistent with this, antibody-secreting 
cells were reported to have increased numbers of somatic 
mutations relative to resting IgG+ MBC (Wrammert et al., 
2008). More comprehensive comparisons of these cell types 
from the same individual are required to fully address this issue.
Analysis of selected HIV-infected individuals with low 
levels of viremia revealed MBC specificities with a diverse rep-
ertoire (Scheid et al., 2009). Indeed, our immunoglobulin gene 
sequencing results of DIII-specific MBCs with WNV confirm 
this. Thus, although the frequency of any given individual 
MBC that produces highly potent neutralizing antibody may 
be low, the breadth of the repertoire allows for recognition of 
divergent epitopes and viruses, resulting in a capacity for broad 
neutralization. Our results support this concept, as the superna-
tant from stimulated MBCs neutralized both WT and variant 
WNV. Nonetheless, only a limited number of MBC clones 
that produce potently neutralizing antibodies and recognize a 
diverse array of HIV strains have been characterized (Walker 
et al., 2009; Corti et al., 2010; Wu et al., 2010).
The ability of MBCs to target variant epitopes was revealed 
in our studies with MBC clones that preferentially recognized 
the mutant compared with the WT epitope in DIII. By LDA, 
we calculated that 10% of our DIII-specific MBC response 
recognized variant protein significantly better than WT protein. 
Our observation of MBCs preferentially recognizing a protein 
variant is analogous to that observed with the anti-HIV gp120 
antibody HJ16, which recognizes a mutant (D368R) gp120 JEM Vol. 208, No. 13  2605
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quantitative ELISA to normalize data between experiments. Neutraliza-
tion data were fit to a variable slope to calculate the EC50 values by   
linear regression.
MBC LDA cultures. WNV-specific MBC frequencies were determined 
by measuring the reactivity of supernatants by LDA to recombinant protein 
by ELISA and was adapted from published protocols (Amanna and Slifka, 
2006). Single cell splenocyte suspensions were generated from WNV-infected 
mice. Erythrocytes were lysed (ACK lysing buffer; Invitrogen) and CD19+ 
B cells isolated by positive selection using magnetic beads (Miltenyi Biotec). 
B cells were resuspended in LDA medium (RPMI, 10% FBS, 1× penicillin-
streptomycin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
10 mM Hepes, and 50 µM -mercaptoethanol). B cells were cultured in 
twofold serial dilutions starting at 50,000–120,000 cells per well in 96-well 
flat-bottom plates in the presence of Staphylococcus aureus Cowan strain (SAC) 
lysate (diluted 1:10,000; Sigma-Aldrich), 1 µg/ml pokeweed mitogen lectin 
(Sigma-Aldrich),  10  µg/ml  lipopolysaccharide  (from  E.  coli  0.111:B4; 
Sigma-Aldrich),  1  µg/ml  phosphorothioated  murine  CpG  (5-TCCAT-
GACGTTCCTGATGCT-3; Integrated DNA Technologies), 16 ng/ml 
mIL-2, 10 ng/ml mIL-6, 17 ng/ml mIL-10 (PeproTech), and 5,000 cells per 
well of irradiated syngeneic splenocytes. Plates were sealed with an adhesive 
lid to prevent evaporation and incubated at 37°C and 5% humidified CO2 
for 6 d. To calculate the frequency of WNV-specific MBC that produced 
IgG, half-area 96-well plates (Corning-Costar) were coated with 5 µg/ml 
WNV E protein overnight at 4°C. Plates were washed and blocked with 
PBS-T for 1 h at 37°C. Supernatants from LDA plates were added to the 
ELISA plates (15 µl per well), and detection of WNV-specific antibody was 
conducted as described in ELISPOT assay. Positive wells were defined as 
wells that scored twofold over the mean OD of negative control wells (wells 
containing irradiated splenocytes and supplements alone). Supernatant from 
cultured naive splenocytes did not score positive, and only LDA that con-
tained at least two positive wells at the highest dilution were analyzed.
Single-cell  MBC  cultures  and  reexpression  of  immunoglobulin 
genes. NIH 3T3 cells (American Type Culture Collection) were retrovi-
rally transduced with a murine stem cell retrovirus (Bhattacharya et al., 2002) 
expressing CD40L-IRES-GFP or BAFF-IRES-human CD4. Antigen-specific 
MBCs were sorted using a FACSAria II into individual wells of a flat-
bottom 96-well plate containing LDA medium supplemented as described 
in the previous section. Each well was seeded with 5,000 mitomycin C–
treated BAFF+CD40L+ NIH 3T3 cells. After 6 d, supernatant was harvested 
and tested for reactivity to DIII or DIII-K307E/T330I by ELISA and total 
RNA was extracted with Trizol (Invitrogen). cDNA was generated, and 
immunoglobulin heavy and light chain genes were amplified by PCR and 
sequenced as previously described (Tiller et al., 2009). Sequences were ana-
lyzed for immunoglobulin genes using IgBlast. Primers for specific Vh, V, 
Jh, and J segments were used to amplify variable regions for both heavy and 
light chain genes (Tiller et al., 2009), and these segments were cloned in-
frame into pEF1-myc-His expression vectors (Invitrogen) downstream of a 
consensus  immunoglobulin  leader  sequence  and  upstream  of  either  the 
mouse C1 or C constant region. Six individual clones of both heavy and 
light chain genes were resequenced, and individual heavy and light chain 
expression constructs containing the consensus sequence without point mu-
tations were cotransfected into 293T cells by calcium phosphate transfection. 
Culture supernatant was harvested 3 d after transfection for ELISA assays.
Online supplemental material. Supplemental material shows the gating 
and sorting strategy of splenic MBC ex vivo (Fig. S1, A and B) and adoptive 
transfer studies in RAG1/ mice (Fig. S1C). Gene family usage (Table S1) 
and  immunoglobulin  CDR  sequences  (Table  S2)  from  WNV-specific 
MBC clones also are described. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20110740/DC1.
We thank M. Slifka and I. Amanna for technical advice, P. Pal for preparing the 
CHIKV stock, and M. Slifka critical comments on the manuscript.
(DIII residues 586–705) proteins were expressed in CHO-S cells (Life 
Technologies). The respective N297Q and K307E/ T330I mutations were 
introduced by site directed mutagenesis using the QuikChange method 
(Agilent Technologies) in the mammalian expression vector pCIneo (Pro-
mega) before transfection. The mutated DIII-Fc proteins were then purified 
from conditioned medium by sequential protein A affinity and size exclusion   
chromatography. After binding of DIII-FcHu, cells were washed and incu-
bated with an Alexa Fluor 488–conjugated goat anti–human IgG antibody 
(Invitrogen). For intracellular staining of antigen-specific LLPCs, bone marrow 
cells were depleted of CD4, CD3, CD19, GR-1, and Ter119 using anti–rat IgG 
magnetic beads (Dynabeads; Invitrogen). Remaining cells were stained for   
surface expression of CD8, CD19, and B220 and CD138. Cells were washed, 
fixed with 4% paraformaldehyde for 10 min, and permeabilized with saponin 
buffer (Hanks balanced salt solution containing 10 mM Hepes and 0.1% wt/vol 
saponin) for 10 min. Intracellular DIII-specific antibody was detected using the 
same method as described for staining of antigen-specific MBCs.
For adoptive transfer experiments, non–B cell lineage cells and IgM+, 
IgD+, CD138+, and GL-7+ cells were depleted with magnetic beads (Dyna-
beads). CD19+CCR6+CD80+ class-switched IgMIgD cells were sorted 
into media (DME supplemented with 10% FBS, 10 mM Hepes, 10 mM 
nonessential amino acids, 10 mM sodium pyruvate, and penicillin and strep-
tomycin) using a FACSAria II (BD). Cells were transferred adoptively by 
retroorbital injection at a fixed 3:1 donor to recipient ratio resulting in 
30,000–140,000 total memory cells per recipient.
Serological analysis. WNV-specific antibody titers in serum were calculated 
as previously described (Oliphant et al., 2007). In brief, 96-well plates (Nalge 
Nunc) were coated with recombinant protein (5 µg/ml DIII or DIII-K307E/
T330I) overnight at 4°C. After blocking for 1 h with PBS supplemented with 
2% BSA and 0.05% Tween 20 at 37°C, diluted serum samples were added to 
wells and incubated for 1 h at room temperature. Plates were washed with PBS 
with 0.05% Tween 20 and incubated with 1 µg/ml biotinylated anti-IgG 
(Sigma-Aldrich) for 1 h. After washing, 2 µg/ml streptavidin-conjugated horse-
radish peroxidase (Invitrogen) was added to each well and plates were incubated 
for 1 h. Plates were developed using tetramethylbenzidine substrate (Dako) and 
quenched with H2SO4. The optical density was read at 450 nm and endpoint 
dilutions were calculated as 3 SD above the background (BSA-coated wells).
ELISPOT assay. Mixed cellulose filter plates (Millipore) were coated initially 
with a capture antibody (100 µl WNV E111 Fab fragment [Sukupolvi-Petty 
et al., 2007] at 40 µg/ml in PBS for 2 h at 37°C), washed twice with 200 µl 
PBS, and then 40 µg/ml of recombinant WNV DIII protein in PBS was 
added overnight at 4°C. Plates were washed twice with PBS with 0.1% 
Tween-20, twice with PBS, and blocked for 1 h at room temperature with 
DME (Sigma-Aldrich) supplemented with 10% FBS, penicillin and strepto-
mycin, 10 mM Hepes, 50 µM -mercaptoethanol, and 10 mM nonessential 
amino acids. Bone marrow cells were depleted of erythrocytes by differential 
centrifugation as described in Flow cytometry and cell sorting, resuspended 
at 2 × 107 cells/ml, and serially diluted into wells. After 5 h at 37°C, plates 
were washed three times with PBS and three times with PBS + 0.1% 
Tween-20 (PBST). Wells were incubated with 1 µg/ml biotinylated anti-
IgG (Sigma-Aldrich) diluted in PBST with 1% FBS and incubated overnight 
at 4°C. After washing with PBST, wells were incubated with streptavidin 
conjugated to 1.25 µg/ml HRP diluted in PBST with 1% FBS. Plates were 
washed a final time with PBST and PBS. Spots were developed using a 
chromogen substrate (AEC [3-amino-9 ethyl-carbazole]; Sigma-Aldrich), 
and the reaction was quenched by thoroughly rinsing wells with water. Spots 
were enumerated using a stereomicroscope.
Neutralization assay. Plaque reduction neutralization assays on BHK21-15 
cells were performed after mixing serial dilutions of serum with a fixed amount 
(102 PFU) of WNV as previously described (Diamond et al., 2003). For MBC 
neutralization assays, MBCs were cultured as described in the next section, and 
pooled supernatant was concentrated using a centrifugal filter device (Millipore) 
before mixing with virus. The concentration of IgG was determined by 2606 Memory B cells are adept at recognizing virus variants | Purtha et al.
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